Wheeley M S, Bolton J C, Campbell D B
Pharmatherapeutica. 1982;3(2):143-52.
A multi-centre general practitioner study was carried out in 2497 hypertensive patients. 81% of whom were already being treated for their condition, to assess the antihypertensive activity and tolerance of indapamide (2.5 mg/day in a single dose) when given in conjunction with or as replacement for existing therapy, if any. The results showed that, over a 3-month period, indapamide produced a gradual reduction in blood pressure (mean decrease of 24/14 mmHg) and there was a direct correlation between the initial diastolic pressure and the observed reduction. Side-effects with indapamide therapy were relatively few and mild, the most frequently reported being nausea, dizziness and headache. There were no consistent changes in any of the haematological or biochemical parameters monitored. An increase was noted in subjective well-being, measured by a visual analogue scale. Analysis of the results in 772 of the patients who were aged over 65 years showed that the response to and tolerance of indapamide was similar to that in younger patients.
一项针对2497名高血压患者的多中心全科医生研究开展。其中81%的患者已在接受针对其病情的治疗，目的是评估吲达帕胺（每日2.5毫克单剂量）与现有治疗联合使用或替代现有治疗（如有）时的降压活性和耐受性。结果显示，在3个月期间，吲达帕胺使血压逐渐降低（平均降低24/14毫米汞柱），且初始舒张压与观察到的血压降低之间存在直接相关性。吲达帕胺治疗的副作用相对较少且轻微，最常报告的是恶心、头晕和头痛。所监测的任何血液学或生化参数均无持续变化。通过视觉模拟量表测量发现主观幸福感有所增加。对772名65岁以上患者的结果分析表明，吲达帕胺的反应和耐受性与年轻患者相似。
